Literature DB >> 4043059

Hepatitis B vaccination campaign in a low endemicity area.

P J Grob, M Rickenbach, R Steffen, S Wagner, G Kistler, M Schmid, F Gutzwiller.   

Abstract

Between January 1982 and December 1983 14,666 high-risk individuals in the Canton of Zurich, which has one million inhabitants, received 36,234 hepatitis B vaccine injections. The annual number of acute hepatitis B cases dropped from an estimated 220 to 280 in 1981 to 177 in 1982 and 133 in 1983. This drop of 40-50% resulted mainly from reduced numbers of cases among health care workers, drug addicts and homosexuals. Vaccination was a factor responsible for the reduced incidence of hepatitis B among health care workers and drug addicts, high-risk categories substantial proportions of which had been vaccinated. There was no evidence of a secondary protective effect of vaccination extending to other high-risk groups.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4043059     DOI: 10.1007/bf02148694

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  8 in total

1.  Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients.

Authors:  J Crosnier; P Jungers; A M Couroucé; A Laplanche; E Benhamou; F Degos; B Lacour; P Prunet; Y Cerisier; P Guesry
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

2.  Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1982-06-25       Impact factor: 17.586

3.  [Street vaccination].

Authors:  U Blumer; M Schär; P J Grob
Journal:  Soz Praventivmed       Date:  1984

4.  Hepatitis B vaccination of high-risk individuals in the canton of Zurich.

Authors:  P J Grob; M Rickenbach; S Wagner; R Steffen; F Gutzwiller
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

5.  Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial.

Authors:  J Desmyter; J Colaert; G De Groote; M Reynders; E E Reerink-Brongers; P N Lelie; P J Dees; H W Reesink
Journal:  Lancet       Date:  1983-12-10       Impact factor: 79.321

6.  Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients.

Authors:  P J Grob; U Binswanger; K Zaruba; H I Joller-Jemelka; M Schmid; W Häcki; A Blumberg; A Abplanalp; W Herwig; H Iselin; C Descoeudres
Journal:  Antiviral Res       Date:  1983-03       Impact factor: 5.970

7.  Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; W R Oleszko; D C William; R Sadovsky; J M Morrison; A Kellner
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

8.  [Epidemiology of hepatitis 1977-1979].

Authors:  U K Widmer; A Villaverde; P J Grob
Journal:  Schweiz Med Wochenschr       Date:  1980-06-14
  8 in total
  1 in total

1.  NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.

Authors:  Ahmad Jalili; Kirsten D Mertz; Julia Romanov; Christine Wagner; Frank Kalthoff; Anton Stuetz; Gaurav Pathria; Melanie Gschaider; Georg Stingl; Stephan N Wagner
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.